ArticleFrontiers in oncology2019

Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 Consortium.

Isabelle Ray-Coquard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.